Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease. - Wikidata - wikimedia - TriplyDB

Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease.

Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease.

http://www.wikidata.org/entity/Q33798313

about

Therapeutic Drug Monitoring of Posaconazole: an Update Emerging issues with diagnosis and management of fungal infections in solid organ transplant recipients Clinical hepatotoxicity associated with antifungal agents.Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis.Evaluation of Sulfobutylether-β-Cyclodextrin Exposure in a Critically Ill Patient Receiving Intravenous Posaconazole While Undergoing Continuous Venovenous Hemofiltration In Vitro Activity of Isavuconazole and Comparators against Clinical Isolates of the Mucorales Order International Evaluation of MIC Distributions and Epidemiological Cutoff Value (ECV) Definitions for Fusarium Species Identified by Molecular Methods for the CLSI Broth Microdilution Method.Pharmacologic and clinical evaluation of posaconazole.Posaconazole: a review of the gastro-resistant tablet and intravenous solution in invasive fungal infections.Review of the new delayed-release oral tablet and intravenous dosage forms of posaconazole.The 'cephalosporin era' of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections.Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.New facets of antifungal therapy.Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience.Efficacy of antifungal prophylaxis with oral suspension posaconazole during induction chemotherapy of acute myeloid leukemia.Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.Posaconazole: An Update of Its Clinical Use.Visual Hallucinations Associated with High Posaconazole Concentrations in Serum.Utility of posaconazole therapeutic drug monitoring and assessment of plasma concentration threshold for effective prophylaxis of invasive fungal infections: a meta-analysis with trial sequential analysis.Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients.

P2860

Q26746016-139E0464-6F14-4B78-AC5B-48CD9229B753 Q28084643-FB7D9859-1C5F-4E90-A366-3AEBA662182D Q34546811-6C8819FF-B517-4BA7-A8AA-E0DA5C1A507C Q34596761-D1D5BB17-A4B2-4AF7-8F64-71F3BB46DF15 Q36076106-26782E7D-6AB0-4057-A4B1-957C0158B2BE Q36290764-7E1EAB9C-76C1-49FC-8667-95AE2CF33F96 Q36571990-92798B47-2F8B-413C-87D1-08C22F2626F6 Q37445943-CC7FEFFC-6AED-424B-97ED-5B950B3BAF16 Q38321383-92CE5258-AB84-434D-A77B-5BFB4391B8B9 Q38341595-A3DA712C-11E2-4C30-A34E-F97E8E4BA466 Q38534865-60A8456D-2C49-4FEC-B907-3377DBBD43F0 Q38681635-742A2392-C636-43C9-A9C8-C310F1F6C758 Q38797864-CB1BC8A9-12E5-4F37-9B32-0ACF72FD730A Q40577292-B0095CDE-0E8B-4124-94C3-D6F7FB513BDE Q41175826-65CBD31C-60D6-47E0-8CB0-70FFDEA127DC Q41993016-614A7118-3A65-4CFC-8F8C-9AEF476D605D Q42144246-91375BB1-7642-4EDA-A39C-450F58709D14 Q42563983-CC55913B-FCC5-42EF-A853-F466290DAACC Q54243380-47A6D0A0-1710-47E4-B194-45E813A9680F Q55236793-3C082B56-0850-419E-B1B9-0490441A27D3

P2860

Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease.

http://www.wikidata.org/entity/Q33798313

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Phase 1B study of the pharmaco ...... k for invasive fungal disease.

@ast

Phase 1B study of the pharmaco ...... k for invasive fungal disease.

@en

type

label

Phase 1B study of the pharmaco ...... k for invasive fungal disease.

@ast

Phase 1B study of the pharmaco ...... k for invasive fungal disease.

@en

prefLabel

Phase 1B study of the pharmaco ...... k for invasive fungal disease.

@ast

Phase 1B study of the pharmaco ...... k for invasive fungal disease.

@en

P1433

Q33798313-237931BD-54C0-42F2-8F19-666295E692AC

P1476

Q33798313-34BB1B41-601C-403C-BC25-8B5C36F490D8

P2093

Q33798313-178B1CDB-18DD-4B52-9D20-480361A6C587

Q33798313-31173D09-9873-48FA-A2ED-CB925953508E

Q33798313-32590814-8E0D-4A83-A835-2123C700296D

Q33798313-33B1E2FE-7718-4292-B93C-11A62EB47DB1

Q33798313-38F4941D-6FFF-4695-AB63-CF58C2B84E20

Q33798313-4B2B52B5-A95C-45B3-8F75-A55B00E9D726

Q33798313-7B52C237-BF9E-45DD-8064-8D6A86139405

Q33798313-D9EB18D0-54C6-4D04-B62F-97E8AB7444CF

P2860

Q33798313-01CF410F-407C-4EAD-BCA8-DE48F475E090

Q33798313-05A21C21-B20D-4DA2-B14B-56104EC46A4B

Q33798313-05C9ADAB-A8DB-497A-8A28-0E1D0183427C

Q33798313-11903095-8D1D-43EC-9B6E-C32A5D9C9E16

Q33798313-1E86A610-C1ED-40B8-93E4-86D2548C12BF

Q33798313-20F083D5-2A2E-4535-8F47-0F5CA486EF8D

Q33798313-22C96942-16C2-4167-AF4F-C86FE5699230

Q33798313-2669E60B-E000-44B7-AB7E-3057EED37F43

Q33798313-286B46C4-882F-4731-972D-E7771C2D9364

Q33798313-74BAF9BE-A5AA-4BA2-94B6-9AD2C6F8CE83

P304

Q33798313-5084E8E7-ECD5-4B19-B306-BC1BF853D0DA

P31

Q33798313-DEF664C0-859C-451B-8CAE-EC381714AA2D

P356

Q33798313-C27DCE6F-A410-4883-BA44-CFEDE05D2C66

P407

Q33798313-2D6A2A01-B72A-48E8-8936-24001AAF5551

P433

Q33798313-2C946495-6F5E-494D-AFDB-EEE2FC0F77D5

P478

Q33798313-A48F9D69-6D95-4543-ABA8-5428AB01111F

P50

Q33798313-6BCAEE4C-B8BC-43AE-8012-C68861338016

Q33798313-EA8530FE-3C62-41E8-9F35-9B55A84F75D8

P577

Q33798313-68B7D210-DF31-4D10-9008-B3AD41C42F9E

P698

Q33798313-E52EB01E-79C8-4E23-9232-13CB7EB321F7

P932

Q33798313-6682E8B3-5121-4013-A483-C9EEF2ABB80A

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Phase 1B study of the pharmaco ...... sk for invasive fungal disease

@en

P2093

Andrew J Ullmann

http://www.w3.org/2001/XMLSchema#string

Gopal Krishna

http://www.w3.org/2001/XMLSchema#string

Hernando Patino

http://www.w3.org/2001/XMLSchema#string

Hetty Waskin

http://www.w3.org/2001/XMLSchema#string

Johan Maertens

http://www.w3.org/2001/XMLSchema#string

Maria Caceres

http://www.w3.org/2001/XMLSchema#string

Michael N Robertson

http://www.w3.org/2001/XMLSchema#string

Nicholas Kartsonis

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

Posaconazole as Salvage Treatment for Invasive Fusariosis in Patients with Underlying Hematologic Malignancy and Other Conditions

A sensitive liquid chromatography and mass spectrometry method for the determination of posaconazole in human plasma.

Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.

Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers.

In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.

Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults.

Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection.

Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring.

P304

3610-3617

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.02686-13

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P50

Oliver A Cornely

P577

2014-04-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24733463

http://www.w3.org/2001/XMLSchema#string

P932

4068540

http://www.w3.org/2001/XMLSchema#string